INNOVIVA, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
INNOVIVA, INC. (INVA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$181.20 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-02-19.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2019-02-19
- INNOVIVA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2014-12-31 was -$3.80M.
- INNOVIVA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2014-09-30 was $0.00.
- INNOVIVA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2017 was -$181.20M, a 979.61% decline from fiscal 2016.
- INNOVIVA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2016 was $20.60M, a 338.30% increase from fiscal 2015.
- INNOVIVA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2015 was $4.70M.
- INNOVIVA, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2014 was -$103.80M, a 248.07% decline from fiscal 2013.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$181.20M 10-K · filed 2019-02-19 | |||
| 2016-12-31 | $20.60M 10-K · filed 2018-02-23 | |||
| 2015-12-31 | $4.70M 10-K · filed 2018-02-23 | |||
| 2014-12-31 | -$3.80M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$3.80M derived: sum of 2 quarters · filed 2017-02-28 | -$103.80M 10-K · filed 2017-02-28 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | -$100.00M 10-Q · filed 2014-11-04 | ||
| 2014-06-30 | -$100.00M 10-Q · filed 2014-08-07 | |||
| 2013-12-31 | $70.10M 10-K · filed 2016-02-24 | |||
| 2012-12-31 | $3.00M 10-K · filed 2015-02-27 | |||
| 2011-12-31 | $50.00M 10-K · filed 2014-03-03 | |||
| 2010-12-31 | $35.00M 10-K · filed 2013-02-26 | |||
| 2009-12-31 | $32.00M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |